Daiichi Sankyo: Hypertension trials

The registry lists 43 Hypertension studies with Daiichi Sankyo as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 2Phase 2 3Phase 3 23Phase 4 15No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Olmesartan Comparison to Losartan in Hypertensive SubjectsCompletedNCT00949884Phase 4Results posted
• Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in HypertensionCompletedNCT00923091Phase 3Results posted
• Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in HypertensionCompletedNCT00902538Phase 3Results posted
• Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential HypertensionCompletedNCT00890591Phase 4Results posted
• Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in HypertensionCompletedNCT00858702Phase 4Results posted
• A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood PressureCompletedNCT00791258Phase 4Results posted
• 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 DiabeticsCompletedNCT00654745Phase 4Results posted
• Safety and Efficacy Study of a Triple Combination Therapy in Subjects With HypertensionCompletedNCT00649389Phase 3Results posted
• Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II HypertensionCompletedNCT00527514Phase 3Results posted
• Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionCompletedNCT00430950Phase 3Results posted
• A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II HypertensionCompletedNCT00430638Phase 4Results posted
• Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionCompletedNCT00430508Phase 3Results posted
• An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With HypertensionCompletedNCT00412932Phase 4Results posted
• An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II DiabetesCompletedNCT00403481Phase 4Results posted
• Olmesartan and an add-on Treatment in Patients With Mild to Moderate HypertensionCompletedNCT00311155Phase 4Results posted
• Olmesartan Pediatric Pharmacokinetic (PK) StudyCompletedNCT00151814Phase 1Results posted
• Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood PressureCompletedNCT00151775Phase 2/3Results posted
• The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy VolunteersCompletedNCT04019652Phase 1
• Study of CS-3150 in Patients With Essential HypertensionCompletedNCT02890173Phase 3
• Study of CS-3150 Compared to Olmesartan in Patients With Essential HypertensionCompletedNCT02848170Not applicable
• Study of CS-3150 in Patients With Severe HypertensionCompletedNCT02808026Phase 3
• Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal ImpairmentCompletedNCT02807987Phase 3
• Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and AlbuminuriaCompletedNCT02807974Phase 3
• Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential HypertensionCompletedNCT02722265Phase 3
• A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal ImpairmentCompletedNCT02448628Phase 2
• A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsCompletedNCT02345044Phase 2
• Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination TherapyCompletedNCT01838850Phase 3
• The Confirmatory Olmesartan Plaque Regression StudyTerminatedNCT01132768Phase 4
• Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood PressureCompletedNCT01101009Phase 4
• Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic SyndromeCompletedNCT00891267Phase 3
• Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential HypertensionCompletedNCT00872586Phase 3
• Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential HypertensionCompletedNCT00856271Phase 3
• Vascular Improvement With Olmesartan Medoxomil StudyCompletedNCT00772499Phase 4
• Isolated Systolic Hypertension in the Elderly and Very ElderlyCompletedNCT00751829Phase 3
• Olmesartan Medoxomil Versus Losartan in Elderly and Very ElderlyCompletedNCT00751751Phase 3
• Olmesartan as an add-on to Amlodipine in HypertensionCompletedNCT00220233Phase 3
• Amlodipine as add-on to Olmesartan in HypertensionCompletedNCT00220220Phase 3
• Olmesartan in Essential HypertensionCompletedNCT00185172Phase 3
• Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe HypertensionCompletedNCT00185133Phase 3
• Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel BlockerCompletedNCT00185120Phase 4
• A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to InsulinCompletedNCT00185094Phase 4
• An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With HypertensionCompletedNCT00185068Phase 4
• Olmesartan Medoxomil in Hypertension and Renal ImpairmentCompletedNCT00151827Phase 3